You are here

Carbohydrate-Based Therapy of Cryptosporidiosis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 2R42AI045194-02
Amount: $250,000.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
478 CLINTON RD CHESTNUT HILL, MA 02167
NEWTON, MA 02167
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HONORINE WARD
 (617) 636-7032
 HWARD@LIFESPAN.ORG
Business Contact
 PEREIRA, MIERCIO A
Phone: (617) 636-2933
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Cryptosporidium parvum is a significant
cause of diarrheal disease of human and veterinary importance worldwide. There
is currently no effective, specific therapy approved for cryptosporidiosis. The
overall goal of this project is to develop safe and effective,
carbohydrate-based and lectin-based therapy for this disease. The rationale for
this type of therapy for cryptosporidiosis is based on the finding that C.
parvum sporozoites express a surface lectin which binds to Galactose and
N-acetylgalactosamine (Gal/GaINAc) residues on host glycoconjugates such as
mucins. Lectin-specific mucins and oligosaccharides-derived from them block
infection of C. parvum in vitro. In addition, sporozoites express
GaINAc-containing mucin-like surface glycoproteins which, are also involved in
infection, raising the possibility that they too may serve as interventional
targets. This is borne out by the finding that exogenous Gal/GaINAc-specific
lectins, which bind to host and parasite mucins, have anti-cryptosporidial
activity in vitro. The specific aims of Phase II are 1) To characterize and
evaluate anti-cryptosporidial activity of mucin oligosaccharides in vivo in
animal models of cryptosporidiosis; 2) To evaluate the therapeutic potential of
exogenous levtins with specificity for parasite and host and mucin
oligosaccharides in vivo 3) To identify and evaluate carbohydrate-based
compounds from a combinedatorial library for anti-cryptosporidial activity in
vitro.

PROPOSED COMMERCIAL APPLICATION:
Not Available

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government